New research on sepsis and the role of NETs in improving diagnosis will be presented at the European Society of Intensive Medicine on Monday October 7. This was flagged in the recent MJA webinar on NETs and their potential as a target for new treatments.
Epigenetics company, Volition, is presenting findings from large, independent studies exploring the potential of using Nu.Q® NETs in clinical practice to enhance sepsis management and is hosting a symposium on ‘NETs in sepsis management’ at ESICM LIVES.
Immune response
Nu.Q® NETs, Volition’s nucleosome quantification technology, is a simple, low-cost, accessible test that quantifies an individual’s level of circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage, and in severe cases, sepsis, organ failure and death. Watch the webinar if you’d like to know more.
The event, will be chaired by Professor Djillali Annane, who is a world-renowned sepsis expert and leading one of the major studies in France.
Dr Andrew Retter, a leading critical care consultant in the UK and Volition’s Chief Medical Officer is also speaking, alongside Dr Caroline Neumann from Jena University Hospital in Germany.
Press release
Here’s Volition’s release with more details, which includes this quote from Prof Annane:
“As a Critical Care Consultant, I see the devastating effects of this disease each day. I believe Nu.Q® NETs, as a diagnostic tool, has the potential to bring about a paradigm shift in sepsis management. I hope that Nu.Q® NETs becomes widely available – in every intensive care unit, in every hospital setting – to help ensure we detect, treat, and monitor sepsis earlier and save lives.”
If you’d like to know more, email Debra Daglish or call on 020 38723954.
Recent Comments